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ABSTRACT 
Objectives: The aim was to update the 2009 EULAR recommendations for the 
treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. 
Methods: Update of the previous treatment recommendations was performed 
according to EULAR standard operating procedures. The task force consisted of 32 
SSc clinical experts from Europe and USA, two patients nominated by the pan-
European patient association for SSc (FESCA), a clinical epidemiologist and 2 
research fellows. All centers from the EULAR Scleroderma Trials and Research 
(EUSTAR) group were invited to submit and select clinical questions concerning SSc 
treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 
different interventions were selected for systematic literature review. The new 
recommendations were based on the available evidence and developed in a 
consensus meeting with clinical experts and patients. 
Results: The procedure resulted in sixteen recommendations being developed 
(instead of 14 in 2009) that address treatment of several SSc-related organ 
complications: Raynaud’s phenomenon (RP), digital ulcers (DUs), pulmonary arterial 
hypertension (PAH), skin and lung disease, scleroderma renal crisis, and 
gastrointestinal involvement. Compared with the 2009 recommendations, the 2015 
recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the 
treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor 
antagonists, prostacyclin analogues, and PDE-5 inhibitors for SSc-related PAH. New 
recommendations regarding the use of fluoxetine for SSc-related RP and 
haematopoietic stem cell transplantation for selected patients with rapidly 
progressing SSc were also added. In addition, several comments regarding other 
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treatments addressed in clinical questions and suggestions for the SSc research 
agenda were formulated. 
Conclusions: These updated data- and consensus-derived recommendations will 
help rheumatologists to manage patients with SSc in an evidence-based way. These 
recommendations also give directions for future clinical research in SSc. 
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INTRODUCTION: 
Systemic sclerosis (SSc) is a connective tissue disease (CTD) which affects skin, 
blood vessels, heart, lungs, kidneys, gastrointestinal tract and musculoskeletal 
system. Involvement of internal organs results in significant morbidity and mortality of 
SSc patients. Clinical complexity and heterogeneity of SSc leaves treatment of this 
disease very challenging.[1] Establishing the first EULAR recommendations for the 
treatment of SSc in 2009 was therefore a milestone for improving care of SSc 
patients and they were well received by the international community of scleroderma 
experts.[2-3] In view of several recent developments regarding treatment of SSc-
related internal organ involvement, the need of an up-date of the 2009 EULAR 
recommendations has been recognized by the EULAR Scleroderma Trials and 
Research group (EUSTAR) and acknowledged by the European League against 
Rheumatism (EULAR). Following EULAR standardized operating procedures, an ad 
hoc expert committee was established by EULAR and EUSTAR.[4-5] As in previous 
recommendations, the global community of SSc experts cooperating within EUSTAR 
was involved.[6] 
Based on the published evidence and expert opinion, 16 up-dated recommendations 
regarding pharmacological treatment of SSc-specific organ involvement were 
formulated. It should be recognized that the field of management of SSc patients is 
larger than pharmacological management alone. Management of SSc also includes 
(early) diagnosis of the disease, early diagnosis of internal organ involvement, 
identification of patients at risk of development for new organ complications and 
deterioration of the disease, as well as non-pharmacological treatments, of which 
most of are beyond the scope of this project. There are also several (potential) drugs, 
including new promising therapies that might be helpful in management of patients 
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with SSc that could not be included in these evidence-based recommendations due 
to insufficient data at present. The actual recommendations are aimed to guide 
pharmacological treatment of SSc-specific organ involvement. These 
recommendations are not meant to replace the physician’s clinical judgement or the 
patient-physician shared decision. They should be viewed in light of the clinician’s 
understanding of the individual patient and the clinician’s and patients’ judgement of 
the balance between the efficacy and toxicity of a treatment. Although some 
treatment-related toxicities are mentioned in the text of the recommendations, it still 
is the responsibility of the physician to recognize and monitor all possible 
toxicities/side effects according to the information supplied by the producer and all 
other available sources. 
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METHODS: 
Design 
These recommendations are an update of the 2009 EULAR recommendations for 
treatment of SSc.[2] Evidence for existing recommendations was updated with new 
evidence published since then, all existing recommendations were newly judged, and 
reformulated if necessary. Existing recommendations could also be removed, for 
instance when a certain (class of) drugs was withdrawn from the market. New 
evidence-based recommendations were added. 
  
Expert panel 
An expert panel was established with 32 clinical experts in the field of SSc (29 
rheumatologists, 1 dermatologist, 2 paediatric rheumatologists with expertise in 
juvenile SSc), 2 patients with SSc (KF, JW) and 1 clinical epidemiologist (JF) overall 
representing 11 countries. The clinical experts had to be internationally recognised 
as specialists in SSc with several years of experience in diagnosing and treating 
patients with this disease. The two patient partners were nominated by the pan-
European patient association for SSc (FESCA). Potential conflicts of interest were 
declared by all participants. There was no involvement of third parties in the entire 
process of making these recommendations. 
   
Selection process of clinical questions 
To create a comprehensive list of topics of interest, clinical experts from all EUSTAR 
centres were asked by e-mail to contribute clinical questions relevant to the 
pharmacological treatment of SSc. As a result, 170 clinical questions were provided 
by experts from 41 EUSTAR centres. These questions were then categorised by 
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drug (class) and aggregated with the clinical questions from 2009; duplicates were 
removed. The clinical questions were phrased according to the ‘PICO’ format 
(Patients, Intervention, Comparator, Outcome). Subsequently, the clinical questions 
were submitted in a 3-round web-based Delphi exercise to members of EUSTAR 
centres, as previously described [6]. The Delphi exercise was completed until May 
2014. For more details regarding the Delphi exercise please see the online 
supplement. 
The results of the Delphi exercise were presented to the expert panel in a first face-
to-face meeting in June 2014. In this meeting the Nominal Group Technique was 
used, based on the results of the Delphi exercise. Finally the clinical questions were 
selected that were subjected to the systematic literature search (online 
supplementary Table S1). 
 
Systematic literature search  
The systematic literature search was performed by two fellows (AK, MB) supervised 
by a task force member (JA), guided by the clinical epidemiologist (JF). For new 
clinical questions, the literature search was performed on all articles published 
between 1966 and, as agreed by the panel, until September 30th, 2014 in Pubmed, 
EMBASE, the Cochrane Database for meta-analyses and the Cochrane Controlled 
Trials Register as well as the 2012 and 2013 EULAR and American College of 
Rheumatology (ACR) congress abstract archives. For clinical questions already 
included in the existing recommendations the same strategy was followed, searching 
from February 2007 to September, 30th, 2014. A standardized search strategy was 
used for all clinical questions (online supplementary table S2). Medical subject 
heading (MeSH) search (exploded) was used for PubMed and a keyword search was 
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used for 2012-2014 or if the MeSH term was not available. For every clinical 
question, the publications found were screened for eligibility by reading title and 
abstract. The reference lists of meta-analyses, reviews or systematic reviews were 
examined to find additional studies. 
For details regarding selection of studies, classifying and evaluation of evidence as 
well as data extraction see online Supplement. 
 
 
Recommendations 
The evidence of the individual studies was combined to achieve a recommendation 
in agreement with the GRADE system.[5, 12] Accordingly, an evidence profile and a 
summary of outcomes table were made for every clinical question by AK or MB. 
Using these results, a set of draft recommendations were prepared by OKB, JF, 
UML, YA and OD. The draft recommendations were sent to the expert panel in 
advance of the second face-to-face consensus meeting in October 2014. Draft 
recommendations were presented one-by-one together with the evidence profile and 
outcome tables, moderated by JF. Based on the nominal group technique, all 
recommendations were discussed, could be reformulated, and a level of evidence 
was attached, until consensus was reached among all participating experts. 
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RESULTS:  
The procedure as described above resulted in sixteen recommendations being 
developed (instead of 14 in 2009). These recommendations address treatment of 
several SSc-related organ complications: Raynaud’s phenomenon (RP), digital ulcers 
(DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma 
renal crisis, and gastrointestinal involvement. The final set of recommendations, 
grouped according to organ systems and the future research agenda are 
summarized in tables 1 and 2, respectively. 
In addition to the main recommendations, the experts decided to formulate,  several 
comments addressing therapeutic modalities  in research questions, of which at 
present neither literature-based evidence nor clinical experience allowed precise 
recommendations to be made (Table S3 in online Supplement). 
 
I. Raynaud phenomenon in SSc patients (SSc-RP) 
1. A meta-analysis of RCTs on dihydropiridine-type calcium antagonists indicates 
that nifedipine reduces the frequency and severity of SSc-RP attacks. A meta-
analysis of RCTs indicates that PDE-5 inhibitors reduce the frequency and severity 
of SSc-RP attacks. Dihydropiridine-type calcium antagonists, usually oral nifedipine, 
should be considered for first-line therapy for SSc-RP. PDE-5 inhibitors should also 
be considered in treatment of SSc-RP. (strength of recommendation: A) 
   
One meta-analysis, including 8 randomized controlled trials (RCTs): seven with 
nifedipine and one with nicardipine, with 109 SSc patients involved, indicated that 
dihydropiridine-type calcium antagonists reduce the frequency and severity of 
ischaemic attacks in SSc-RP.[13-20] The weighted mean difference (WMD) of all 
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calcium antagonists versus placebo (six trials) for the reduction in the number of 
ischaemic attacks over a 2-week period was -8.31 (95% CI –15.71 to -0.91). When 
the five RCT evaluating nifedipine (10–20 mg three times a day) versus placebo were 
analysed separately, the reduction was greater with a WMD of -10.21 (95% CI -20.09 
to -0.34).  
None of the studies included into meta-analysis has directly examined the side 
effects of calcium antagonists in SSc. Hypotension, dizziness, flushing, dependent 
oedema, and headaches are believed to be fairly common side effects of these 
agents.[13] 
Another meta-analysis of 6 RCTs (2 with sildenafil, 3 with tadalafil and 1 with 
vardenafil) including 236 patients with CTD-related Raynaud’s phenomenon, of 
whom 95% were patients with SSc, showed that phosphodiesterase type 5 (PDE-5) 
inhibitors improve frequency, severity and duration of RP attacks.[21-27] The 
treatment effect (mean difference; 95% confidence interval (95%CI)) for daily 
frequency (-0.49; -0.71 to -0.28), severity (-0.46; -0.74 to -0.17) and daily duration of 
RP (-14.62; -20.25 to -9.00 min) although significant, was only moderate. 
Side effects associated with usage of PDE-5 inhibitors were common and include 
different forms of vasomotor reactions, myalgias, allergic reaction, chest pain, 
dyspepsia, nasal stuffiness, and visual abnormalities. 
Considering long term experience and good safety profile, experts recommend that 
calcium channel blockers should be used as first line therapy for SSc-RP and 
PDE-5 inhibitors in SSc patients with severe RP and/or those who do not 
satisfactorily respond to calcium channel blockers. 
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2. A meta-analysis of RCTs on prostanoids indicates that intravenous iloprost 
reduces the frequency and severity of SSc-RP attacks. Intravenous iloprost should 
be considered for severe SSc-RP (strength of recommendation: A). 
Experts recommend that i.v. iloprost should be used for treatment of SSc-RP attacks 
after oral therapy.  
 
One meta-analysis, including five RCTs with intravenous iloprost, one RCT with oral 
iloprost and one RCT with oral cisaprost, with 332 SSc patients in total, indicates that 
iloprost is effective in reducing the frequency and severity of SSc-RP.[28-35] Iloprost, 
given intravenously (0.5–3 ng/kg per minute for 3–5 consecutive days sequentially) 
or orally (50–150 µg twice a day) significantly reduced the frequency of ischaemic 
attacks, and improved the RP severity score in comparison with placebo (WMD; 95% 
CI: -17.46; -19.19 to -15.73 and -0.69; -1.12 to -0.26, respectively). Oral prostanoids 
seem to be generally less effective than intravenous iloprost in the treatment of SSc-
RP, although some beneficial effects could be seen with higher doses.[34-38] 
Two RCTs comparing intravenous iloprost (0.5–2 ng/kg per minute for 3–5 days, 
every 6–8 weeks) with nifedipine (30–60 mg/day) indicate that iloprost is only slightly 
superior to nifedipine in improving symptoms of SSc-RP.[18, 39] 
In view of costs and feasibility, the experts recommended that intravenous 
prostanoids are considered when oral therapies (including calcium channel blockers 
and PDE-5 inhibitors) have failed. As most drugs used for treating RP may induce 
vascular side effects, the experts recommend particular attention if prostanoids 
are combined with other vasodilators. 
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3. One small study indicates that fluoxetine might improve SSc-RP attacks. 
Fluoxetine might be considered in treatment of SSc-RP attacks. (strength of 
recommendation: C) 
  
One small study including subgroup analysis of 27 patients with SSc-related RP 
indicates that fluoxetine (p.o. 20 mg/day) was superior to nifedipine LA (p.o. 40 
mg/day) in reduction of severity of RP and comparable with nifedipine in reduction of 
frequency of RP attacks in patients with SSc.[40] The latter effect was not significant 
in SSc patients neither for fluoxetine nor for nifedipine, which could be due to the low 
number of SSc patients included. Safety results, available for the combined group of 
patients with primary RP (n=26) and SSc-related RP (n=27) indicated that fluoxetine 
was better tolerated than nifedipine: withdrawals due to adverse effects were more 
than twice higher in the nifedipine group as compared with fluoxetine. Main reasons 
leading to treatment withdrawals in the fluoxetine group were: apathy, lethargy and 
impaired concentration. 
Despite the relatively low quality of published evidence, experts recognize that 
fluoxetine is used in practice and believe that fluoxetine is a useful alternative 
for treatment of SSc-related RP, in particular in SSc patients who cannot tolerate or 
do not respond to vasodilators.  
Since the data regarding the use of fluoxetine in SSc patients is limited and 
fluoxetine, as a serotonin-specific reuptake inhibitor and antidepressant, may have 
potential effects on the central nervous system or heart it is important to consider 
potential contraindications before starting treatment and to carefully monitor patients 
for side effects when on fluoxetine, in particular during long-term treatment  
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[https://www.medicines.org.uk/emc/medicine/25737]. Of note, withdrawal symptoms 
when treatment is discontinued are common, particularly if discontinuation is abrupt. 
 
 
II. Digital ulcers in SSc patients 
4. Two RCTs indicate that intravenous iloprost is efficacious in healing digital 
ulcers in patients with SSc. Intravenous iloprost should be considered in the 
treatment of digital ulcers in patients with SSc. (strength of recommendation: A) 
 
Intravenous iloprost (0.5–2 ng/kg per minute for 3–5 consecutive days) significantly 
reduced the number of DUs in comparison with placebo in one small RCT (Jadad 
score 3), and improved DUs healing in another RCT (Jadad score 4) including 73 
SSc patients with active DUs (p=0.06 vs placebo for 50% improvement).[32-33] In 
addition, two RCTs comparing intravenous iloprost with oral nifedipine suggest that 
both medications have a beneficial effect on DUs but the number of patients with 
DUs in both trials was small.[18, 39] 
One meta-analysis published in 2013 included, in addition to the 2 abovementioned 
RCTs with intravenous iloprost, 2 additional RCTs, one with oral iloprost (100 µg/day 
or 200 µg/day versus placebo for 6 weeks) and one with oral treprostinil (slow 
release up to 16 mg bid for 20 weeks).[37, 41] This analysis revealed a trend towards 
a beneficial effect of prostanoids over placebo for healing of DUs (the pooled risk 
ratio (RR); 95%CI) for number of patients with DUs improvement or healing: 1.33; 
0.97 to 1.84, p=0.08).[42] The greatest mean effect was seen with intravenous 
iloprost (RR;95%CI: 3.00; 0.76 to 11.81). 
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The results of this meta-analysis summarizing the effect of 4 RCTs (2 with iv iloprost, 
one with oral iloprost and one with oral beraprost) did not show significant effects of 
prostanoids for the prevention of new DUs in SSc (RR; 95%CI for number of patients 
with new DUs: 0.85; 0.68 to 1.08, p=0.19).[42] Again, the greatest effect was seen 
with iv iloprost (RR; 95%CI: 1.18; 0.30 to 4.72). When the results of the small study 
by Wigley et al. were evaluated separately, they suggest that intravenous iloprost 
may prevent new DUs in SSc patients (standardized mean difference (SMD); 95%CI 
for number of DUs: -0.77; -1.46 to -0.08, p=0.03).[32, 42] Moreover, a RCT with 
epoprostenol, administered continuously for severe SSc-related pulmonary arterial 
hypertension (SSc-PAH), revealed a tendency towards a reduction in the number of 
new digital ulcers (by 50%). 
Considering the fact that oral prostanoids showed lower efficacy for treatment of 
SSc-related Raynaud’s phenomenon, as compared with iv iloprost (see section on 
RP), the experts decided, based on the results of the above-mentioned 2 RCTs, to 
recommend intravenous iloprost as a treatment for DUs in SSc patients. Further 
studies are required to confirm beneficial effect of iv iloprost in prevention of 
development of DUs in SSc patients. In view of risk of side effects and route of 
administration usually requiring hospitalization, intravenous iloprost should be 
considered in particular in SSc patients with DUs not responding to oral therapy. In 
severe cases, combination therapy with oral vasodilator and i.v. iloprost can be used. 
However, the increased risk of side effects should be taken into account. 
  
5. A meta-analysis of RCTs and results of an independent RCT indicate that PDE-5 
inhibitors improve healing of digital ulcers in patients with SSc. Moreover, the 
results of one small RCT indicate that PDE-5 inhibitors may prevent development of 
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new digital ulcers in SSc. PDE-5 inhibitors should be considered in the treatment of 
digital ulcers in SSc patients. (strength of recommendation: A) 
 
One meta-analysis of 3 RCTs investigating various selective PDE-5 inhibitors 
(sildenafil 50 mg twice daily, modified release sildenafil 100 mg/day increased up to 
200 mg/day or tadalafil 20 mg on alternate days) in SSc patients with Raynaud’s 
phenomenon of whom 39 had baseline DUs indicated that selective PDE-5 inhibitors 
improve healing of DUs in SSc patients.[42] Although DUs healing was a co-primary 
outcome only in 1 of 3 RCTs included into the meta-analysis, and all 3 RCTs were 
underpowered to detect difference between active treatment and placebo, the pooled 
effect shows significant benefit of PDE-5 inhibitors over placebo on DUs healing.[23, 
42] Both, the number of patients with DUs healing and the number of patients with 
DUs improvement were significantly higher for PDE-5 inhibitors as compared with 
placebo (RR; 95%CI): 3.28; 1.32 to 8.13, p<0.01 for DUs healing and 4.29; 1.73 to 
10.66, p<0.002 for DUs improvement, respectively).[42] The results of this meta-
analysis are corroborated by an independent multicentre RCT evaluating the effect of 
tadalafil (20 mg/d on alternate day for 8 weeks as an add-on-therapy to previous 
vasodilators) on DUs healing, as one of two co-primary end-points together with 
effect on Raynaud’s phenomenon, in 31 SSc patients with baseline DUs.[26] After 8 
weeks of treatment, DUs healed completely in 14 out of 18 patients in the tadalafil 
group as compared to 5 out of 13 patients in the placebo arm (p<0.05). The results of 
this study including altogether 53 SSc patients with SSc-related Raynaud’s 
phenomenon indicate that tadalafil was also associated with significantly lower risk of 
new DUs: new DUs developed in 1 out of 27 patients from the tadalafil group as 
compared to 9 out of 26 patients from the placebo group (p<0.05). Tadalafil (20 mg/d 
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on alternate day for 6 weeks with one week wash out period, as add-on-therapy to 
previous vasodilators) prevented development of new DUs in another single-centre 
cross-over RTC including 24 SSc patients with secondary RP, 23 (95%) of whom had 
SSc, cited in the meta-analysis by Tingey at al.[25, 42] In this study, only 1 new DU 
developed under tadalafil treatment as compared with 13 new DUs which developed 
in 6 patients under placebo treatment (p<0.05).  
Side effects of PDE-5 inhibitors are discussed in the previous paragraph regarding 
PDE-5 inhibitors in treatment of Raynaud’s phenomenon. 
Based on these data, the experts concluded that PDE-5 inhibitors can be 
efficacious in treating SSc-related DUs. Whether other than tadalafil PDE-5 
inhibitors can prevent development of new DUs in SSc patients needs to be clarified 
in further studies.  
Annotation: The recently published SEDUCE trial did not reach statistical 
significance with respect to the influence of sildenafil (20 mg three times daily for 12 
weeks) on time to DUs healing, in part due to unexpectedly high healing rates in 
placebo group.[43] The study did show significant reduction in the number of DUs per 
patient at week 8 (1.23±1.61 in sildenafil group vs 1.79±2.40 in placebo group, 
p=0.04) and week 12 (0.86±1.62 vs 1.51±2.68, p=0.01 respectively) as a result of a 
greater healing rate. Since the experts discussed the impact of the study not 
unambiguously, and the sildenafil dose used in SEDUCE study was lower than in 
the studies included in the abovementioned meta-analysis by Tingey et al., the 
results of this study, which was published after data closure for the 
recommendations, did not change the respective recommendation [42-43]. 
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6. Bosentan has confirmed efficacy in two high-quality RCTs to reduce the number 
of new digital ulcers in SSc patients. Bosentan should be considered for reduction of 
the number of new digital ulcers in SSc, especially in patients with multiple digital 
ulcers despite use of calcium channel blockers, PDE-5 inhibitors or iloprost therapy. 
(strength of recommendation: A).  
 
The effect of bosentan, a dual receptor antagonist, on DUs prevention and healing 
was evaluated in two high quality RCTs (RAPIDS-1 and RAPIDS-2) including 
altogether 310 SSc patients with a history of or at least one active DU at baseline. 
Bosentan, given orally at a dose of 62.5 mg twice a day for 4 weeks followed by 125 
mg twice a day for 12 weeks in RAPIDS1 or 20 weeks in RAPIDS2, significantly 
reduced the number of new DUs in both trials.[44, 45] In a recent meta-analysis of 
RAPIDS1 and RAPIDS2, treatment with bosentan was associated with a significant 
reduction in the mean number of DUs per patient in the overall trials population 
(SMD; 95% CI: -0.34; -0.57 to -0.11, p=0.004) and in SSc patients with baseline DUs 
(SMD; 95% CI: -0.36; -0.61 to -0.11, p=0.005).[42] The effect of bosentan was most 
pronounced in SSc patients with multiple (4 or more) DUs at baseline (ES; 95%CI: -
0.52; -1.01 to -0.02) as compared with SSc patients with lower number of DUs at 
baseline (ES; 95%CI: -0.08; -0.44 to 0.28) in RAPIDS2.[45] 
The reduction in the number of patients with a new DU was not statistically significant 
in any of the RAPIDS trials or their meta-analysis.[44-45] 
Neither trial indicated that bosentan is superior to placebo in the healing of SSc-
related active DUs, as evaluated by the time to complete or partial healing of DUs 
present at baseline, the time to healing of all DUs, or the percentage of patients with 
complete DUs healing (p>0.05 vs placebo for all comparisons). At present, there is 
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insufficient evidence that endothelin receptor antagonists (ERA) have beneficial 
effects on SSc-RP attacks either. 
 
There are two major concerns related to the use of bosentan and other ERA: 
potential liver injury and teratogenicity. Hormonal contraceptives may not be reliable 
if co-administered with bosentan, because bosentan may reduce their efficacy by 
interference with the cytochrome P450 system. 
In view of the results of both RAPIDS trials and considering potential toxicities 
associated with bosentan, experts recommend usage of bosentan especially in 
patients who have multiple DUs despite treatment with other vasodilators such 
as calcium channel blockers, PDE-5 inhibitors and iloprost to prevent the 
development of new DUs. 
The results of the RAPIDS-2 trial which were published in full in 2011 did not support 
the difference in response to bosentan between patients with limited and diffuse SSc 
subsets, an aspect, which was suggested by the subanalysis of the RAPIDS-1 trail 
[44-45]. Because of these data, the experts decided that in the present 
recommendations bosentan should be considered for reduction of new DUs in all 
SSc patients with DUs, independent of the disease subset. 
 
Annotation: It should be noted that the effect of bosentan on the prevention of new 
DUs in SSc has not been proven for other ERA. The results of two double-blind 
RCTs (DUAL-1 and DUAL-2), which were published after closure of literature 
research deadline, did not show a significant difference between macicentan, a 
selective antagonist of ET-1 receptors, and placebo in prevention of new DUs over 
16 weeks in SSc patients with active DUS at baseline [Khanna D et al. Effect of 
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Macitentan on the Development of New Ischemic Digital Ulcers in Patients With 
Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA 
2016;315:1975-88]
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III. SSc-PAH 
7. Based on the results of high-quality RCTs including heterogeneous population of 
PAH patients, including CTD-PAH, several ERA (ambrisentan, bosentan, and 
macitentan), PDE-5 inhibitors (sildenafil, tadalafil) and riociguat have been 
approved for treatment of PAH associated with connective tissue diseases, ERA, 
PDE-5 inhibitors or riociguat should be considered to treat SSc-related PAH. 
(strength of recommendation: B extrapolation from RCTs including SSc/CTD 
patients) 
 
High quality RCTs involving patients with different forms of PAH, including CTD-
related PAH, indicate that endothelin antagonists (bosentan, ambrisentan, and 
macitentan) improve exercise capacity and time to clinical worsening in patients with 
PAH.[46-48] Adverse events associated with ERA treatment in these clinical trials 
included abnormal liver function tests, peripheral oedema, palpitations, headache, 
chest pain, nasal congestion, and anaemia, but the safety profile differed for specific 
agents.[48]  
Sitaxentan, a selective endothelin receptor antagonist which was included in the 
2009 EULAR recommendations for the treatment of SSc, has been withdrawn from 
the market in December 2010 due to its hepatotoxicity.[2, 47]   
High quality RCTs involving heterogeneous PAH patients, including CTD-PAH, 
indicate that selective PDE-5 inhibitors (sildenafil, and tadalafil) improve exercise 
capacity in patients with PAH and (tadalafil 40 mg/day) reduce risk of clinical 
worsening (reviewed in ref 47 and 48).[47-48] The most common side effects 
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associated with PDE-5 inhibitors included flushing, dyspepsia, diarrhoea, headache, 
and myalgia. 
Another RCT including patients with different forms of PAH, including CTD-PAH 
patients, showed that riociguat, a soluble guanylate cyclase stimulator, improves 
exercise capacity, time to clinical worsening and hemodynamic parameters in PAH 
patients.[49] Drug-related serious adverse events included syncope, increased 
hepatic enzyme levels, dizziness, acute renal failure, and hypotension.[49] 
Based on the results of these high quality RCTs, endothelin receptor antagonists 
(bosentan, ambrisentan, and macitentan), selective PDE-5 inhibitors (sildenafil, and 
tadalafil) and riociguat have been approved for treatment of PAH associated with 
connective tissue diseases.[47, 50-51] The evidence regarding usage of these drugs 
specifically in SSc-related PAH is less robust. 
Experts recommend that ERA, selective PDE-5 inhibitors and riociguat should 
be considered in the treatment of SSc-related PAH in agreement with 
international guidelines regarding treatment of PAH.[47] This has been 
underlined by the publication of the recently published new guidelines of the 
pulmonology societies.[52] 
In severe or progressing PAH cases combination therapy with different PAH-specific 
drugs should be taken into account. Although at the time of developing these 
recommendations RCTs comparing combination therapy with PAH-specific drugs 
versus monotherapy in SSc-PAH patients were lacking, this approach is in line with 
recent guidelines of the European cardiology and pulmonology societies regarding 
management of PAH in general, and seems particularly important in SSc-PAH 
patients known to have more progressive disease that patients with other forms of 
PAH.[52]   
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8. One high-quality RCT in SSc patients indicates that continuous intravenous 
epoprostenol improves exercise capacity, functional class and haemodynamic 
measures in SSc-PAH. Intravenous epoprostenol should be considered for the 
treatment of patients with severe SSc-PAH (class III and IV). (strength of 
recommendation: A) 
Based on the results of high-quality RCTs including heterogeneous PAH patients, 
including CTD-PAH, other prostacyclin analogues (iloprost, treprostinil) have 
also been registered for treatment of PAH associated with connective tissue 
diseases. Prostacyclin analogues should be considered for the treatment of patients 
with SSc-PAH. (strength of recommendation: B: extrapolation from RCTs including 
SSc/CTD patients) 
  
One RCT (Jadad score 3), involving 111 SSc-PAH patients, showed that 
epoprostenol (continuous intravenous infusion, starting dose 2 ng/kg per minute and 
increased based on clinical symptoms and tolerability) in combination with 
conventional therapy (diuretics, oral anticoagulants, oxygen and glycosides), 
improves exercise capacity, functional status and haemodynamic measures in SSc-
PAH, compared with conventional therapy.[53] The median 6MWT distance improved 
by 108 m (95% CI 55m to 180m; p=0.001; epoprostenol vs control group), NYHA 
functional class improved in 21 (38%) patients treated with epoprostenol and none in 
the control group (NNT 2.7) and the Borg dyspnoea index and the dyspnoea fatigue 
score also improved significantly. The beneficial haemodynamic effects of 
epoprostenol included a statistically significant decrease in pulmonary vascular 
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resistance, mean pulmonary artery pressure and right atrial pressure, as well as a 
significant increase in cardiac index.[53] 
Based on the results of the RCT and two large long-term observational studies, 
which have documented an improvement in survival of patients with idiopathic PAH 
treated with epoprostenol, intravenous epoprostenol has been approved by the FDA 
for the treatment of severe (WHO class III or IV) PAH.[47-48, 54-55]. 
As a result of a very short half-life, epoprostenol is administered through a permanent 
indwelling central venous catheter, which may incite adverse events: infections, 
pneumothorax and haemorrhage.[56] Sudden disruption/withdrawal of intravenous 
epoprostenol (due to catheter/vein thrombosis and/ or patient’s decision) may lead to 
life-threatening PAH rebound. Based on overall risk-to-benefit considerations, 
and in agreement with the current guidelines, experts recommend intravenous 
epoprostenol as the treatment of choice in severe, therapy-resistant SSc-PAH, 
which are in line with those of recently published guidelines of other 
societies.[47, 52]  
Based on the results of high quality RCTs involving patients with different forms of 
PAH, including patients with CTD-PAH, other prostacyclin analogues such as 
treprostinil (intravenous, subcutaneous, or inhaled) and iloprost (inhaled), have been 
approved for treatment of PAH, including PAH associated with CTD.[47-48] Side 
effects associated with usage of iv treprostinil are similar to that reported with iv 
epoprostenol and include headache, jaw pain, diarrhoea, abdominal pain, anorexia, 
vomiting, photosensitivity, cutaneous flushing, and arthralgias, as well as the risk of 
complications associated with continuous infusion via catheter. Subcutaneous 
infusion of prostanoids is frequently associated with pain at the infusion site. Inhaled 
prostanoids can result in cough, headache, flushing, nausea, and syncope [48]. 
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Despite the lack of specific RCTs evaluating these drugs exclusively in SSc 
patients, experts recommend that these prostacyclin analogues should be 
considered for treatment of SSc-PAH, in agreement with international 
guidelines for PAH treatment.[47, 52] 
The experts concluded that combining different classes of PAH-specific 
therapies may be considered in the treatment of selected SSc-PAH patients, 
especially in those with severe or progressing disease. As discussed in previous 
paragraph, this approach is in line with recently published guidelines regarding 
management of PAH in general, and seems particularly important in SSc-PAH 
patients known to have more progressive disease that patients with other forms of 
PAH.[52] 
  
IV. Skin and lung disease 
9. Two RCTs and their re-analysis have shown that methotrexate improves skin 
score in early diffuse SSc. Positive effects on other organ manifestations have not 
been established. Methotrexate may be considered for treatment of skin 
manifestations of early diffuse SSc. (strength of recommendation: A) 
 
In one RCT (Jadad score 3), involving 29 SSc patients with diffuse SSc or limited 
SSc (mean duration of skin involvement 3.2 years), methotrexate (intramuscularly at 
a dose of 15 mg/week for 24 weeks) showed a trend towards improvement of the 
total skin score (p=0.06 vs placebo).[57] 
In the second RCT (Jadad score 5), involving 73 patients with early diffuse SSc, 
methotrexate, given orally at a dose of 10 mg per week for 12 months, decreased the 
University of California Los Angeles (UCLA) skin score (ES 0.5, 95%: CI 0.0 to 1.0) 
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and the modified Rodnan skin score (mRSS, ES 0.5; 95%: CI 0.0 to 0.9) compared 
with placebo in an intention-to-treat analysis.[58] A beneficial effect of methotrexate 
(over placebo) on skin manifestations has been confirmed by a re-analysis of the trial 
by Pope et al. which, using a Bayesian methodology, showed that the probability that 
methotrexate improves mRSS and the UCLA skin score were 94% and 96%, 
respectively.[58-59] No significant effects on other organ manifestations were shown. 
In the study evaluating early dSSc patients, eleven out of 36 patients (31%) in the 
placebo group and 12 out of 35 patients (34%) in the methotrexate group dropped 
out before study completion, mainly due to treatment inefficacy. There were few 
premature discontinuations due to adverse events (number needed to harm 16 and 
34.5 in both RCT, respectively). There were no significant differences in the mortality 
rate (three vs seven; p=0.18), although the trend was in favour of methotrexate.[58] 
Safety concerns associated with methotrexate include liver toxicity, pancytopenia, its 
potential teratogenicity and, possibly, the induction of lung injury.[60] It should be 
noted that in both RCTs evaluating methotrexate in SSc, relatively low dose of 
methotrexate was used. Whether higher doses of methotrexate, which are used in 
treatment of rheumatoid arthritis and other inflammatory diseases, could increase 
treatment effectiveness without significant increase in risk of side effects remains to 
be established. In paediatric patients methotrexate dose of 25 mg/m2/week p.o. or 
s.c is well tolerated. 
Thus, the experts confirmed the earlier recommendation for methotrexate in 
early diffuse SSc. 
It should be recognized that cyclophosphamide (CYC) has also been shown, in 
RCTs, to improve skin changes in SSc patients, and other agents such as 
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mycophenolate mofetil or azathioprine are used to treat skin involvement, although 
their efficacy has not been studied extensively.[61] 
  
 
10. In view of the results from two high-quality RCTs and despite its known toxicity, 
cyclophosphamide should be considered for treatment of SSc-ILD, in particular for 
SSc patients with progressive ILD. (Strength of recommendation: A) 
 
The evidence regarding efficacy of CYC in SSc-related interstitial lung disease (SS-
ILD) results mainly from two high quality (Jadad score 5) RCTs and their sub-
analyses.[61-62] The first trial (Scleroderma Lung Study, SLS), involving 158 SSc 
patients with active alveolitis, demonstrated that CYC given orally at a dose of 1–2 
mg/kg per day improved lung volumes, dyspnoea score and quality of life over 12 
months compared with placebo.[61] The placebo-corrected mean (95% CI) 
improvement in forced vital capacity (FVC) and total lung capacity (TLC) was 2.5% 
(0.3% to 4.8%) and 4.1% (0.5% to 7.7%), respectively (p=0.03 for both measures). 
No significant effect on diffusing lung capacity for carbon monoxide (DLCO) could be 
demonstrated. Cyclophosphamide also improved the transitional dyspnoea index, the 
HAQ disability index, and the vitality and health-transition domains of the Short-Form 
36 (p<0.05 vs placebo for all measures).[61] Sub-analysis of the SLS revealed that 
CYC therapy was also associated with significant improvement in HRCT score.[63] 
Extension of the SLS study showed that the FVC continued to improve after 
cessation of CYC treatment reaching a maximum at 18 months: 6 months after 
stopping CYC therapy (mean FVC difference versus placebo: 4,16%, p=0.01).[64] 
The beneficial effects of CYC disappeared one year after CYC was terminated. The 
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effect of CYC was greater in patients with more severe lung and/or skin disease.[64-
65] The mean FVC improvement in patients with baseline FVC lower than 70% of 
predicted was 4.62% at 12 months and 6.8% at 18 months (p<0.006 for both time 
points), while in patients with baseline FVC > 70% of predicted the mean treatment 
effect was 0.55% at 12 months and 2.67% 18 months (p> 0.05 for both time points). 
Another sub-analysis of the SLS study revealed that the HRCT score and skin 
disease were independent predictors of response to CYC therapy.[65] In patients 
with 50% or more of any lung zone involved by reticular infiltrates on HRCT and/or 
with mRSS of at least 23/51, the CYC treatment effect was 9.81% at 18 months 
(p<0.001) versus no treatment effect (0.58% difference, p>0.05) in patients with less 
severe HRCT findings and a lower mRSS at baseline. 
The second trial evaluated CYC (intravenously at a dose of 600 mg/m2 per month) 
compared with placebo in 45 SSc patients with SSc-ILD.[62] Active treatment 
included six infusions of CYC given at 4-week intervals followed by oral azathioprine 
(2.5 mg/kg per day) or placebo for 6 months. Prednisolone (20 mg on alternate days) 
was co-administered in the active treatment group. The mean adjusted between-
group difference in forced vital capacity was 4.2% in favour of CYC, which just 
missed statistical significance (p=0.08). The lung diffusing capacity for carbon 
monoxide and other outcome measures did not improve.[62] 
Considering the results of both RCTs and the fact that the benefit of CYC was mainly 
due to inhibition of progression of SSc-ILD, experts recommend that CYC therapy 
should be considered in particular in patients with progressive lung disease. As in the 
previous 2009 recommendations there was unanimous consensus of the experts 
with respect to the CYC dose and duration of treatment to be tailored 
individually dependent on the clinical condition and response. Potential risks of 
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bone marrow suppression, teratogenicity, gonadal failure and haemorrhagic cystitis 
must be always considered.[66] 
 
11. Regarding haematopoietic stem cell transplantation (HSCT), two RCTs have 
shown improvement of skin involvement and stabilization of lung function in SSc 
patients and one large RCT reports improvement in event-free survival in SSc 
patients as compared to cyclophosphamide in both trials. HSCT should be 
considered for the treatment of selected patients with rapidly progressive SSc at risk 
of organ failure. In view of the high risk of treatment related side effects and of early 
treatment related mortality, careful selection of SSc patients for this kind of treatment 
and the experience of the medical team are of key importance. (strength of 
recommendation: A)  
   
The results of two RCTs evaluating the efficacy and safety of high dose 
immunosuppressive therapy with subsequent haematopoietic stem cell 
transplantation (HSCT) have been published so far.[67, 68] The first single-centre 
trial (Jadad 3), including 19 SSc patients with mRSS >14 and internal organ 
involvement or mRSS<14 and SSc-ILD, showed that HSCT (200 mg/kg CYC and 
rabbit antithymocyte globulin 6.5mg/kg intravenously in total, preceded by CYC 
2g/m2 and filgastrim as part of the mobilization step prior to leukapheresis) was 
superior to CYC (intravenously, 1g/m2 per month for 6 months) therapy with respect 
to improvement of skin score and lung volumes.[67] No significant effect on diffusing 
capacity of the lungs for carbon monoxide could be demonstrated.  
Another multicentre RCT (ASTIS) compared HSCT (200 mg/kg CYC and rabbit 
antithymocyte globulin 7.5mg/kg intravenously in total, preceded by CYC 4 g/m2 and 
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filgrastim as part of the mobilization step) with CYC pulse therapy (intravenously, 
750mg/m² per month for 12 months) in 156 SSc patients with early diffuse SSc, 
mRSS >/= 15 and internal organ involvement or with an mRSS > 20 without internal 
organ involvement.[68] HSCT was associated with increased treatment-related 
mortality in the first year (8 deaths in HSCT group versus none in CYC group, 
p=0.007) but significantly improved long-term event-free survival (HR; 95%CI: 0.52; 
0.28-0.96, p=0.04 and 0.34; 0.16-0.74, p=0.006 at 1 and 3-through 10-year follow-up) 
and overall survival (HR; 95%CI: 0.48; 0.25-0.91, p=0.02 and 0.29; 0.13-0.64, 
p=0.002 at 1 and 3-through 10-year follow-up). HSCT therapy resulted in significant 
improvement in the mRSS (mean difference; 95% CI: 11.1; 7.3 to 15.0, p< 0.001), 
FVC (mean difference; 95% CI: 9.1; 14.7 to 2.5, p=0.004) and TLC (mean difference; 
95% CI: 6.4; 11.9 to 0.9, p=0.02) at 2 years’ follow-up. No significant effect on DLCO 
could be found. Mean change in creatinine clearance was significantly worse in the 
HSCT group than in the control group (mean difference; 95% CI: 10.9; 1.5 to 20.3 p = 
0.02). Causes of treatment-related deaths in HSCT included Epstein-Barr virus 
reactivation, lymphoma, heart failure, myocardial infarction, and acute respiratory 
distress syndrome. HSCT therapy was also associated with higher risk of viral 
infections (27.8% in the HSCT group vs 1.3% in the control group p< 0.001). 
In view of the results of the two RCTs and considering the risk of potential treatment-
related mortality and morbidity experts recommend that HSCT should be 
considered for the treatment of selected patients with rapidly progressive SSc 
at risk of organ failure. To reduce the risk of treatment-related side effects, HSCT 
should be performed in selected centres with experience in this kind of treatment. 
Careful evaluation of the benefit to risk ratio in individual SSc patients selected for 
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HRCT should be done by experts. Further studies should help to identify subgroups 
of SSc patients in whom HSCT would be most beneficial. 
  
V. Scleroderma renal crisis (SRC) 
12. Several cohort studies showed benefit in survival with use of ACE inhibitors in 
patients with SRC. Experts recommend immediate use of ACE inhibitors in the 
treatment of SRC. (strength of recommendation: C) 
  
RCTs evaluating the efficacy of ACE inhibitors in the treatment of SRC are lacking.  
Since the first report demonstrating a beneficial effect of ACE inhibitors in two 
patients with SRC, numerous case reports and uncontrolled studies have reported on 
ACE inhibitors in SRC.[69-75] A prospective analysis of 108 patients with SRC has 
suggested that patients on ACE inhibitors (captopril in 47 and enalapril in eight) had 
a significantly better survival rate at 1 year (76%) and 5 years (66%) compared with 
patients not on ACE inhibitors (15% at 1 year and 10% at 5 years, respectively). The 
beneficial effect of ACE inhibitors on survival in SRC remained significant after 
adjustment for age and blood pressure (p=0.001).[71] Another prospective 
uncontrolled study of 145 patients with SRC treated with ACE inhibitors 
demonstrated survival rates at 5 and 8 years after the onset of SRC of 90% and 
85%, respectively.[72] Two more recent retrospective studies including 91 and 110 
patients with SRC respectively, the majority of whom (91% and 98% respectively) 
were treated with ACE inhibitors and/or angiotensin receptor antagonists (ARA) 
reported survival rates from 71% to 82% at 1 year, 59% to 60% at 5 years and 42% 
to 47% at 10 years.[74, 75]. In comparison, 3 out 7 (43%) patients without 
ACEI/ARA-2 died within the first months after SRC onset.[74] 
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It is highly unlikely that a formal RCT will be conducted in this rare condition with high 
mortality. Despite the lack of RCTs, experts recommend the use of ACE inhibitors in 
the treatment of SCR. Experts believe that an immediate start of high-dose ACE 
inhibitors in patients who develop SRC is of key importance for improving their 
outcome. ACE inhibitors should be continued long-term as long as  there is any 
chance for additional improvement in kidney function. 
The experts decided also to highlight that published evidence does not 
support the preventive use of ACE inhibitors to decrease risk of development 
or improve outcome of SCR.[73-74, 76] 
  
13. Several retrospective studies suggest that glucocorticoids are associated with a 
higher risk of SRC. Blood pressure and renal function should be carefully monitored 
in SSc patients treated with glucocorticoids. (strength of recommendation: C) 
 
Evidence regarding the impact of steroid use on the development of SRC comes 
mainly from retrospective studies most of which showed significant association 
between steroid exposure and the occurrence of SRC.[70, 73-74, 77-80] 
A case–control analysis including 220 SSc patients showed that 36% of patients with 
SRC had received prednisone at a dose of 15 mg/day or more within 6 months 
preceding the onset of SRC, compared with 12% matched controls (odds ratio; 95% 
CI: 4.4; 2.1 to 9.4; p<0.001).[77] 
Another analysis of the main risk factors for SRC suggested that patients with a high 
skin score, joint contractures and prednisone use (10 mg/day in nine out of 10 
patients) were at higher risk (43% versus 21% of patient without steroids) of 
SRC.[78] 
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In two more recent studies, including 518 and 410 SSc patients, respectively, steroid 
use (adjusted odd ratio; 95% CI: 4.98; 1.52 to 16.3, p=0.008 and hazard ratio; 
95%CI: 1.105; 1.004 to 1.026, p=0.006, respectively) was an independent predictor 
of SRC.[74, 79] A risk to develop SRC increased by 1.5% for every mg of 
prednisone/day consumed the trimester prior SRC.[79] 
A retrospective analysis including 140 patients with SRC showed that high doses of 
steroids (prednisone >/= 30 mg/day) were used more frequently in SSc patients with 
normotensive SRC (64%) as compared with those with hypertensive SCR (16%) 
suggesting an association between the use of high dose steroids and the risk of 
normotensive SRC which is associated with worse prognosis.[70] 
The experts recognize that glucocorticoids, which are used in SSc, are part of the 
therapeutic strategy in the management of ILD, diffuse cutaneous disease or 
musculoskeletal involvement, although the evidence regarding their efficacy is SSc is 
limited [Iudici M et al. Clin Rheumatol. 2014;33:153-64]. Considering the potential risk 
of SRC associated with steroid use experts recommend that SSc patients treated 
with steroids should be carefully monitored with respect to the development of 
SRC. 
 
 
VI. SSc-related gastrointestinal disease 
14. Despite the lack of large, specific RCT, experts recommend that PPIs should 
be used for the treatment of SSc-related gastroesophageal reflux and 
prevention of oesophageal ulcers and strictures (strength of recommendation: B). 
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Large, specific RCT for the efficacy of PPI in patients with SSc are lacking. A small 
RCT indicated that PPI may improve upper GI symptoms in SSc patients.[81] The 
efficacy of PPI in the treatment of GERD in the general population is well 
documented in meta-analyses of RCTs.[82-84] 
In asymptomatic SSc patients, PPI should be used with caution since long-term 
therapy with PPIs might lead to nutritional deficiencies, possibly due to reduced 
intestinal absorption, or increased risk of infections.[85-87] 
   
15. Despite the lack of RCTs in SSc patients, experts recommend that prokinetic 
drugs should be used for the management of SSc-related symptomatic motility 
disturbances (dysphagia, GERD, early satiety, bloating, pseudo-obstruction, etc). 
(strength of recommendation: C) 
  
Small RCTs involving SSc or CTD patients indicate that the short-term usage of 
cisapride has a beneficial effect on gastric emptying and lower oesophageal 
sphincter pressures.[88-92] However, in many countries cisapride has either been 
withdrawn or has limited access as a result of reports about long QT syndrome 
caused by cisapride, which predisposes to severe arrhythmias.[93] 
Long-term efficacy RCTs of other prokinetics in SSc were not found. Several non-
randomized or uncontrolled studies suggest that prokinetics may improve 
gastrointestinal signs and symptoms in SSc patients.[94-97] 
Several prokinetic drugs have shown beneficial effects in RCTs involving patients 
with other than SSc-related dysmotility disorders or are under evaluation (for review 
see ref. 98 and 99).[98-99] 
 36 
The experts conclude that all available prokinetic drugs can be applied to SSc 
patients with GI involvement on an individual basis, in consideration of 
potential benefit to risk ratio. Whether these drugs would be effective in the 
treatment of SSc-related symptomatic motility disturbances in a general manner is at 
present only speculative and needs urgently to be investigated.  
    
16. Despite the lack of RCTs in SSc patients, experts recommend the use of 
intermittent or rotating antibiotics to treat symptomatic small intestine 
bacterial overgrowth in SSc patients. (strength of recommendation: D)  
  
Two small uncontrolled, non-randomized studies suggest that treatment with 
antibiotics might improve symptoms in SSc patients with small intestine bacterial 
overgrowth (SIBO).[100-101] No RCTs regarding the efficacy of antibiotics in the 
treatment of SSc-related bacterial overgrowth or malabsorption were found. 
In general, treatment of symptomatic small intestinal bacterial overgrowth is based on 
empirical courses of one or more broad-spectrum antibiotics with activity against both 
aerobic and anaerobic enterobacteria such as quinolones, amoxicillin-clavulanic acid, 
metronidazole, neomycin, or doxycycline. The principles of diagnosis and treatment 
strategies of this condition have been summarized in an excellent review.[102] 
  
Internal evaluation of recommendations 
All task force members took part in the online-based evaluation of the updated 
recommendations. The results of this evaluation are presented in Table 1. All but one 
recommendation received mean scores of more than 7 indicating high level of 
agreement. The mean score for the recommendation regarding fluoxetine for the 
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treatment of SSc-related RP was 6.06 which is consistent with medium level of 
agreement.  
 
 
 
 
 
 
Table 1. The updated EULAR recommendations for treatment of systemic 
sclerosis, according to the organ involvement, including strength of the 
recommendations and the results of internal evaluation within the task force 
group. 
Organ 
involvement  
Recommendation Strength 
of 
recomm
endation 
Results 
of 
internal 
evaluati
on 
I. Raynaud 
phenomenon 
in SSc 
patients 
(SSc-RP) 
A meta-analysis of RCTs on dihydropiridine-type calcium 
antagonists indicates that nifedipine reduces the frequency 
and severity of SSc-RP attacks. A meta-analysis of RCTs 
indicates that PDE-5 inhibitors reduce the frequency and 
severity of SSc-RP attacks. Dihydropiridine-type calcium 
antagonists, usually oral nifedipine, should be considered for 
first-line therapy for SSc-RP. PDE-5 inhibitors should also be 
considered in treatment of SSc-RP. 
A 8.19 
A meta-analysis of RCTs on prostanoids indicates that 
intravenous iloprost reduces the frequency and severity of SSc-
RP attacks. Intravenous iloprost should be considered for 
severe SSc-RP. 
Experts recommend that i.v. iloprost should be used for 
treatment of SSc-RP attacks after oral therapy.  
A 8.29 
One small study indicates that Fluoxetine might improve SSc-
RP attacks. Fluoxetine might be considered in treatment of 
SSc-RP attacks. 
C 6.06 
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II. Digital 
ulcers in SSc 
patients 
Two RCTs indicate that intravenous iloprost is efficacious in 
healing digital ulcers in patients with SSc. Intravenous iloprost 
should be considered in the treatment of digital ulcers in 
patients with SSc. 
A 8.39 
A meta-analysis of RCTs and results of an independent RCT 
indicate that PDE-5 inhibitors improve healing of digital ulcers 
in patients with SSc. Moreover, the results of one small RCT 
indicate that PDE-5 inhibitors may prevent development of new 
digital ulcers in SSc. PDE-5 inhibitors should be considered in 
treatment of digital ulcers in SSc patients. 
A 8.03 
Bosentan has confirmed efficacy in two high-quality RCTs to 
reduce the number of new digital ulcers in SSc patients. 
Bosentan should be considered for reduction of the number of 
new digital ulcers in SSc, especially in patients with multiple 
digital ulcers despite use of calcium channel blockers, PDE-5 
inhibitors or iloprost therapy. 
A 8.19 
III. SSc-PAH Based on the results of high-quality RCTs including 
heterogeneous population of PAH patients, including CTD-
PAH, several ERA (ambrisentan, bosentan, and macitentan), 
PDE-5 inhibitors (sildenafil, tadalafil) and riociguat have been 
approved for treatment of PAH associated with connective 
tissue diseases. ERA, PDE-5 inhibitors or riociguat should be 
considered to treat SSc-related PAH. 
B 8.32 
One high-quality RCT in SSc patients indicates that continuous 
intravenous epoprostenol improves exercise capacity, 
functional class and haemodynamic measures in SSc-PAH. 
Intravenous epoprostenol should be considered for the 
treatment of patients with severe SSc-PAH (class III and IV). 
A 8.10 
Based on the results of high-quality RCTs including 
heterogeneous population of PAH patients, including CTD-
PAH, other prostacyclin analogues (iloprost, treprostinil) 
have also been registered for treatment of PAH associated with 
connective tissue diseases. Prostacyclin analogues should be 
considered for the treatment of patients with SSc-PAH.  
B 
IV. Skin and 
lung disease 
Two RCTs and their re-analysis have shown that methotrexate 
improves skin score in early diffuse SSc. Positive effects on 
other organ manifestations have not been established. 
Methotrexate may be considered for treatment of skin 
manifestations of early diffuse SSc. 
A 7.42 
In view of the results from two high-quality RCTs and despite its 
known toxicity, cyclophosphamide should be considered for 
treatment of SSc-ILD, in particular for SSc patients with 
progressive ILD. 
A 7.84 
Regarding haematopoietic stem cell transplantation (HSCT), 
two RCTs have shown improvement of skin involvement and 
A 8.03 
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stabilization of lung function in SSc patients and one large RCT 
reports improvement in event-free survival in SSc patients as 
compared to cyclophosphamide in both trials. HSCT should be 
considered for treatment of selected patients with rapidly 
progressive SSc at risk of organ failure. In view of the high risk 
of treatment related side effects and of early treatment related 
mortality, careful selection of SSc patients for this kind of 
treatment and the experience of the medical team are of key 
importance. 
V. 
Scleroderma 
renal crisis 
(SRC) 
Several cohort studies showed benefit in survival with use of 
ACE inhibitors in patients with SRC. Experts recommend 
immediate use of ACE inhibitors in the treatment of SRC. 
C 8.52 
Several retrospective studies suggest that glucocorticoids are 
associated with a higher risk of SRC. Blood pressure and renal 
function should be carefully monitored in SSc patients treated 
with glucocorticoids. 
C 8.10 
VI. SSc-
related 
gastrointestin
al disease 
Despite the lack of large, specific RCT, experts recommend 
that PPI should be used for the treatment of SSc-related 
gastroesophageal reflux and prevention of oesophageal ulcers 
and strictures 
B 8.58 
Despite the lack of RCTs in SSc patients, experts recommend 
that prokinetic drugs should be used for the management of 
SSc-related symptomatic motility disturbances (dysphagia, 
GERD, early satiety, bloating, pseudo-obstruction, etc). 
C 7.97 
Despite the lack of RCTs in SSc patients, experts recommend 
the use of intermittent or rotating antibiotics to treat 
symptomatic small intestine bacterial overgrowth in SSc 
patients. 
D 8.10 
For explanations of the abbreviations see the text 
  
Research agenda 
In addition to the recommendations, experts formulated a research agenda which 
addresses usage of pharmacological treatments in SSc or SSc-related organ 
complications which were considered of particular interest- Table 2. This research 
agenda can be helpful in developing further clinical research in SSc. 
 
Table 2. Research agenda  
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Research agenda 
1. Evaluation of the efficacy and safety of cyclophosphamide in the treatment of early 
diffuse SSc 
2. Evaluation of the efficacy and safety of mycophenolate mofetil and azathioprine in 
the treatment of SSc 
3. Evaluation of the efficacy and safety of anti-CD20 therapies in the treatment of 
SSc 
4. Evaluation of calcium antagonists in the prevention of SSc-PAH 
6. Evaluation of calcium antagonists in the treatment of digital ulcers in SSc 
7. Evaluation of statins in the treatment of digital ulcers in SSc 
8. Evaluation of the efficacy and safety of ACE inhibitors in the prevention of SRC 
9. Evaluation of the efficacy of non-pharmacological treatments in SSc 
For explanations of the abbreviations see the text 
 
DISCUSSION 
As compared with the previous (2009) EULAR recommendations for treatment of 
SSc, the updated recommendations include several new treatments for specific SSc-
related organ involvement. The greatest changes have been made in treatments of 
vascular complications of SSc and mirror the progress which had been made in this 
field during the last several years. These include the introduction of PDE-5 inhibitors 
for SSc-related Raynaud’s phenomenon and digital ulcers, riociguat and new aspects 
for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for 
SSc-related PAH. The new recommendation regarding the use of fluoxetine for SSc-
related Raynaud’s phenomenon was also added.  
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With regard to treatment of other than vascular complications of SSc, the 
recommendation for haematopoietic stem cell transplantation (HSCT) for selected 
patients with rapidly progressive SSc at risk of organ failure has been added.  
Similar to the 2009 recommendations, the present recommendations address only 
pharmacological treatments which were considered most relevant and received 
consensus from the expert panel. As SSc is an uncommon and clinically 
heterogeneous disease, appropriate testing of therapies is difficult. Indeed, evidence 
supporting the present recommendations is often limited and some of the 
recommendations are supported by the evidence extrapolated from studies involving 
patients with diseases other than SSc or are based solely on expert opinion. 
Similar to the 2009 recommendations, there is still not sufficient data, to make 
specific recommendation for paediatric patients. It would be important to have studies 
at least for the effective paediatric dose of each medication, to be safely applied. 
It should be recognized that there are several other promising therapies, including 
immunosuppressive drugs or new biological agents which could not be included in 
the present recommendations because the evidence for their efficacy was 
considered insufficient at the time of developing these recommendations. The results 
of RCT evaluating new therapies in SSc patients which were published after closure 
of the systematic literature research are presented in table S4 in online Supplement. 
The first of these trials evaluated the efficacy of sildenafil in DUs healing in SSc 
patients and is addressed in the comment following recommendation concerning 
treatment of DUs.[43] 
Another double-blind, phase 2 RCT involved 87 SSc patients with early diffuse SSc 
and elevated acute phase reactants. Treatment with tocilizumab (s.c. 162 mg per 
week) was associated with a favourable trends in skin score improvement as 
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compared with placebo after 24 weeks (p=0.09) and 48 weeks (p=0.06). In addition, 
encouraging changes in FVC were noted. In view of promising effects of tocilizumab 
on skin and lung involvement, it is concluded that further studies are warranted 
before definitive conclusions can be made about its risks and benefits in SSc. [103] 
The results of another RCT, the Scleroderma Lung Study 2 comparing 
mycophenolate mofetil with CYC in patients with SSc-related ILD are expected to be 
published soon. The preliminary results of this study, recently published as an 
abstract of the 2015 ACR annual congress, indicate that mycophenolate mofetil (up 
to 3 g/day orally for 2 years) was comparable with oral CYC (2 mg/kg/day for one 
year followed by matching placebo for the second year) with regard to FVC course at 
24th months.[104] However, final conclusions regarding the place of mycophenolate 
mofetil in the treatment of SSc-related ILD cannot yet be made. Other therapies, 
considered promising by the experts, were addressed in the research agenda (Table 
2). Since “lack of evidence of efficacy” does not imply that “efficacy is absent” the 
absence of positive recommendation regarding specific drug should not be 
interpreted as a contraindication for its use.  
It should also be emphasized that there are other treatment options, such as 
education, physiotherapy or local management of ischemic lesions which were 
beyond the scope of the project or could not be included in the present 
recommendations due to lack of consensus among the experts.  
In conclusion, it is believed that these updated recommendations will help to improve 
care of SSc patients in an evidence-based way and indicate direction for further 
clinical research. Considering the significant complexity and heterogeneity of SSc 
and the limited evidence for treatments, it is recommended that SSc patients should 
be referred to specialized centres with appropriate expertise in SSc management.  
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